5 Drugs Stocks Nudging The Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 100 points (0.7%) at 14,812 as of Monday, April 29, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,173 issues advancing vs. 733 declining with 124 unchanged.

The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.8%. Top gainers within the industry include Watson Pharmaceuticals ( WPI), up 5.4%, Actavis ( ACT), up 5.5%, Novo Nordisk A/S ( NVO), up 2.1%, Pfizer ( PFE), up 1.4% and AstraZeneca ( AZN), up 1.1%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.69.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $2.81 (3.84) to $75.97 on heavy volume Thus far, 2.4 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $74.32-$76.57 after having opened the day at $75.18 as compared to the previous trading day's close of $73.16.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $22.4 billion and is part of the health care sector. Shares are up 22.4% year to date as of the close of trading on Friday.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Sanofi ( SNY) is up $1.12 (2.10) to $54.48 on average volume Thus far, 1.1 million shares of Sanofi exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $53.98-$54.66 after having opened the day at $54.44 as compared to the previous trading day's close of $53.36.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $142.9 billion and is part of the health care sector. The company has a P/E ratio of 28.7, above the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Biogen Idec ( BIIB) is up $10.18 (4.77) to $223.77 on heavy volume Thus far, 1.3 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $219.35-$225.00 after having opened the day at $219.71 as compared to the previous trading day's close of $213.59.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.0 billion and is part of the health care sector. The company has a P/E ratio of 34.3, above the S&P 500 P/E ratio of 17.7. Shares are up 47.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Abbott Laboratories ( ABT) is up $0.32 (0.88) to $36.78 on light volume Thus far, 1.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $36.40-$36.79 after having opened the day at $36.49 as compared to the previous trading day's close of $36.46.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $57.3 billion and is part of the health care sector. The company has a P/E ratio of 9.8, below the S&P 500 P/E ratio of 17.7. Shares are up 11.3% year to date as of the close of trading on Friday.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.64 (0.75) to $85.76 on light volume Thus far, 3.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.8 million shares. The stock has ranged in price between $84.91-$85.89 after having opened the day at $85.04 as compared to the previous trading day's close of $85.12.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $238.4 billion and is part of the health care sector. The company has a P/E ratio of 21.7, above the S&P 500 P/E ratio of 17.7. Shares are up 21.4% year to date as of the close of trading on Friday.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Johnson & Johnson Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error